相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Theodosios D. Filippatos et al.
CURRENT VASCULAR PHARMACOLOGY (2019)
Bempedoic Acid (ETC-1002) A Current Review
Anum Saeed et al.
CARDIOLOGY CLINICS (2018)
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions
Vasilios Kotsis et al.
JOURNAL OF HYPERTENSION (2018)
Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment
Vasilios Kotsis et al.
JOURNAL OF HYPERTENSION (2018)
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials
Ju Jianqing et al.
PHYTOMEDICINE (2018)
Evaluating bempedoic acid for the treatment of hyperlipidaemia
Peter Penson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects
Kyoung Lok Min et al.
CLINICAL THERAPEUTICS (2017)
ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia
Amy C. Burke et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Statin-Ezetimibe Combination Therapy In Diabetic Individuals
Theodosios D. Filippatos et al.
ANGIOLOGY (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Alberico L. Catapano et al.
ATHEROSCLEROSIS (2016)
Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
Kyung-Jin Kim et al.
CARDIOVASCULAR THERAPEUTICS (2016)
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
Ozlem Bilen et al.
CURRENT ATHEROSCLEROSIS REPORTS (2016)
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance
Paul D. Thompson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel
Maciej Banach et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia
Anil Pareek et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
Francesco Di Pierro et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGET & THERAPY (2015)
Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study
S. Achuthan et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone
Anil Pareek et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Combine and conquer: advantages and disadvantages offixed-dose combination therapy
D. S. H. Bell
DIABETES OBESITY & METABOLISM (2013)
Fenofibrate and the kidney: an overview
Michael S. Kostapanos et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients
Giuseppe Derosa et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
The Effects of Berberine on Blood Lipids: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Hui Dong et al.
PLANTA MEDICA (2013)
A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
Theodosios D. Filippatos
CARDIOVASCULAR DRUGS AND THERAPY (2012)
Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals
Emileigh Mercer et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Ahai Luvai et al.
CLINICAL MEDICINE INSIGHTS-CARDIOLOGY (2012)
Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study)
Harold E. Bays et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes
Valerie Hutchins et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
Aris P. Agouridis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Theodosios D. Filippatos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia
A. P. Agouridis et al.
LIPIDS (2011)
Hydroxychloroquine Use Associated With Improvement in Lipid Profiles in Rheumatoid Arthritis Patients
Stephanie J. Morris et al.
ARTHRITIS CARE & RESEARCH (2011)
Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia A Randomized, Double-Blind Study
Eli M. Roth et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Changes in Glycosylated Hemoglobin After Initiation of Hydroxychloroquine or Methotrexate Treatment in Diabetes Patients With Rheumatic Diseases
Laura R. Rekedal et al.
ARTHRITIS AND RHEUMATISM (2010)
NPC1L1 and cholesterol transport
Jenna L. Betters et al.
FEBS LETTERS (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression
Hao Zhang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Fenofibric Acid In Combination Therapy in the Treatment of Mixed Dyslipidemia
Lily P. H. Yang et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2009)
Efficacy and Tolerability of Atorvastatin/Fenofibrate Fixed-Dose Combination Tablet Compared With Atorvastatin and Fenofibrate Monotherapies in Patients With Dyslipidemia: A 12-Week, Multicenter, Double-Blind, Randomized, Parallel-Group Study
Michael H. Davidson et al.
CLINICAL THERAPEUTICS (2009)
Pleiotropic Effects of Fenofibrate
V. Tsimihodimos et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
Jean-Charles Fruchart et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Berberine decreases PCSK9 expression in HepG2 cells
Jamie Cameron et al.
ATHEROSCLEROSIS (2008)
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Theodosios Filippatos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis
Mary Chester M. Wasko et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Deficiency of Niemann-Pick C1 like 1 prevents atherosclerosis in ApoE-/- mice
Harry R. Davis et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER study)
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
NPC1L1: Evolution from pharmacological target to physiological sterol transporter
Murray W. Huff et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: Benefits versus risks
JM McKenney
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
KK Koh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
PN Durrington et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Hepatobiliary excretion of berberine
PL Tsai et al.
DRUG METABOLISM AND DISPOSITION (2004)
Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption
SW Altmann et al.
SCIENCE (2004)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial
JA de Lemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
WJ Kong et al.
NATURE MEDICINE (2004)
Herbal modulation of P-glycoprotein
SF Zhou et al.
DRUG METABOLISM REVIEWS (2004)
The global burden of chronic diseases - Overcoming impediments to prevention and control
D Yach et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial
CM Ballantyne et al.
CIRCULATION (2003)
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
MH Davidson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Inhibition of intestinal cholesterol absorption by ezetimibe in humans
T Sudhop et al.
CIRCULATION (2002)
The involvement of P-glycoprotein in berberine absorption
GY Pan et al.
PHARMACOLOGY & TOXICOLOGY (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
VG Athyros et al.
DIABETES CARE (2002)
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries -: Principal results from EUROASPIRE II Euro Heart Survey Programme
K Kotseva et al.
EUROPEAN HEART JOURNAL (2001)
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia
DN Kiortsis et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
The Lipid Treatment Assessment Project (L-TAP) -: A multicenter survey to evaluate the percentages of dyslipidemic, patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
TA Pearson et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
分享论文
